Because there is no vaccine or cure for HIV, treatment with antiretroviral medications is vital to reduce the spread of the virus, and PEPFAR is a key player in funding those treatments in developing countries. According to UN data, countries that received PEPFAR support saw a 52% reduction in new HIV cases in 2023 compared to 2010, while globally the reduction is only 38%. The DREAMS program, a public-private partnership led by PEPFAR, supports women and girls in combatting structural and behavioral factors that increase the risk of infection and make their lives harder in other ways.
The positive impacts also extend to the broader healthcare system in PEPFAR-aided countries, with the program supporting 327,000 health workers in communities that need them. Overall per-capita GDP growth was on average 2.1 percentage points higher in countries receiving PEPFAR investment than would otherwise be expected.
The U.S. government must uphold its commitment to combat HIV by fully supporting PEPFAR so that those currently receiving care will continue to receive it, and to enable PEPFAR to build on its great success and expand access to others who still lack care and treatment. Robust support for PEPFAR will help to meet the United Nation’s goal of ending the HIV/AIDS epidemic by 2030.
Please urge your members of Congress to reauthorize PEPFAR and keep the U.S. as a leader in the global fight against HIV/AIDS.
Additional Resources
“Assessing PEPFAR’s Impact: Analysis of Economic and Educational Spillover Effects in PEPFAR Countries” report from KFF
December 2024 Global Results & Projections Factsheet from the State Department
Episcopal Church Resolutions